PENTASA Drug Patent Profile

When do Pentasa patents expire, and when can generic versions of Pentasa launch?

Pentasa is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in PENTASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pentasa

A generic version of PENTASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Summary for PENTASA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	130
Clinical Trials:	25
Patent Applications:	1,465
Drug Prices:	Drug price information for PENTASA
Drug Sales Revenues:	Drug sales revenues for PENTASA
What excipients (inactive ingredients) are in PENTASA?	PENTASA excipients list
DailyMed Link:	PENTASA at DailyMed

See drug prices for PENTASA

See drug sales revenues for PENTASA

Recent Clinical Trials for PENTASA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bogomolets National Medical University	N/A
Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine	N/A
AIDS Healthcare Foundation	Phase 1/Phase 2

See all PENTASA clinical trials

Pharmacology for PENTASA

Drug Class

Aminosalicylate

US Patents and Regulatory Information for PENTASA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PENTASA	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	020049-001	May 10, 1993		RX	Yes	No
Takeda Pharms Usa	PENTASA	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	020049-002	Jul 8, 2004	AB	RX	Yes	Yes

Expired US Patents for PENTASA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	PENTASA	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	020049-001	May 10, 1993
Takeda Pharms Usa	PENTASA	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	020049-001	May 10, 1993

International Patents for PENTASA

See the table below for patents covering PENTASA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S57500432
World Intellectual Property Organization (WIPO)	8102671

Market Dynamics and Financial Trajectory for PENTASA (Mesalamine)

Last updated: January 27, 2026

---

Executive Summary

Pentasa (mesalamine) is an anti-inflammatory drug primarily used for ulcerative colitis treatment, marketed by Almirall. As of 2023, the drug maintains a significant position within the inflammatory bowel disease (IBD) therapeutics segment. This report analyzes the current market landscape, growth drivers, challenges, and financial trends impacting PENTASA, integrating recent data, competitive positioning, and regulatory insights.

---

1. Product Overview

Parameter	Details
Generic Name	Mesalamine (5-aminosalicylic acid)
Brand Name	PENTASA (manufactured by Almirall)
Indications	Ulcerative Colitis (mild to moderate), Maintenance therapy
Formulation	Oral tablets, controlled-release capsules, enema formulations
Approval Date	1992 (U.S.), wider global approvals thereafter

---

2. Market Size and Share

Global Inflammatory Bowel Disease (IBD) Market (2022-2027) Estimates:

Segment	2022 Value (USD billion)	CAGR (2022-2027)	Notes
Total IBD Therapeutics	$8.8	5.3%	Driven by rising prevalence
Aminosalicylates (includes mesalamine)	$1.2	4.5%	Leading therapy for ulcerative colitis

PENTASA’s Market Share:

• Estimated 15-20% within mesalamine formulations (2023)
• Dominant in some European markets due to early patent protection and formulary inclusion

3. Market Drivers

Driving Factors	Details
Increasing Prevalence of IBD	1.6 million Americans affected; global rise especially in Asia-Pacific and Latin America
Age Demographics	Rising IBD incidence in adolescents and adults aged 15-35
Treatment Guidelines	Recommendations favoring aminosalicylates as first-line therapy
Formulation Advances	Development of controlled-release and targeted-delivery formulations that improve adherence

4. Challenges and Limitations

Challenges	Impact
Patent Expiry and Generic Competition	Increased generics, pressure on pricing
Therapeutic Alternatives	Biologic agents (e.g., infliximab, vedolizumab) gaining market share for moderate to severe cases
Price Pressures & Reimbursement Policies	Especially in Europe and North America, impacting profitability
Patient Compliance	Blistering adherence due to dosing frequency and side effect profiles

5. Patent and Regulatory Landscape

Patent Status	Details	Implication
Original Patents	Filed in late 1980s, expired in key markets (e.g., U.S. 2011)	Opens market to generics
Market Exclusivities	Some formulations (e.g., controlled-release) protected until 2025	Provides temporary insulation from generics
Regulatory Approvals	Approved in key markets including FDA (1992), EMA, PMDA (Japan)	Facilitates multinational sales

6. Competitive Landscape

Major Competitors	Products	Market Position	Key Strengths/Weaknesses
AbbVie	Apriso (mesalamine), Lialda	Moderate to high	Strong presence in North America, formulations with improved dosing
Takeda	Asacol HD	High	Proven efficacy, established market share pre-generic release
Almirall	PENTASA	Regional leader	Early formulation patents, established efficacy
Generic Suppliers	Mesalamine generics	Largest volume segment	Lower price point, limited branding

---

7. Financial Trajectory (2022-2027)

Parameter	2022	2023 Projection	2024-2027 CAGR	Notes
Global Sales (USD million)	$150	$170	4.5-5%	Modest growth driven by increased IBD diagnosis
Market Share (Regional)	North America: 40%	Stable	N/A	High penetration in North America
Pricing Dynamics	Stable to slight decline	Due to generic entry	N/A	Price erosion expected post-patent expiry

Note: PENTASA's revenues are expected to plateau or decline slightly in absence of line extensions, but sales can be supported through geographic expansion and formulary access.

8. Policy and Reimbursement Environment

Region	Key Policies	Impact on PENTASA
United States	CMS Reimbursement Policies	Favor use of generics over branded drugs
European Union	HTA (Health Technology Assessment) strictness	Impact on pricing and formulary inclusion
Asia-Pacific	Increasing government funding for IBD	Opportunity for growth

---

9. Future Trends and Innovations

Trend	Details	Implication for PENTASA
Biologic and Small Molecule Alternatives	Growing use in moderate/severe IBD	May cannibalize mesalamine volumes
Personalized Medicine	Genetic screening for therapy selection	Could limit overall market if precision therapies replace mesalamine
Formulation Innovations	Enema, foam, or targeted-delivery systems	May improve adherence, extend product lifecycle
Market Expansion	Emerging markets with rising IBD prevalence	Opportunity for growth in Asia, Latin America

---

10. SWOT Analysis

Strengths	Weaknesses
Established brand with regulatory approvals	Patent expiration leading to generic competition
Formulation diversity (oral, enema)	Limited pipeline innovation
Strong regional market presence	Price pressures and reimbursement challenges

Opportunities	Threats
Geographic expansion into emerging markets	Entry of biosimilars and biologics
Formulation advancements	Pricing erosion post-generic entry
Potential line extensions or combination therapies	Shifts in clinical guidelines favoring biologics

---

Conclusion

The market for PENTASA faces a transition phase driven by patent expirations and competition from lower-cost generics. While its position remains robust within specific regions, particularly Europe and North America, its long-term growth prospects depend on geographic expansion, formulation innovations, and evolving treatment paradigms. The rising prevalence of IBD globally offers expansion opportunities, but must be balanced against competitive pressures from biologic agents and new therapies.

---

Key Takeaways

• Market Position: PENTASA retains a significant regional footprint but faces imminent patent cliffs, with generic competition pressing down prices.
• Growth Drivers: Rising IBD incidence globally, improved formulation options, and expanding markets in Asia-Pacific present growth avenues.
• Challenges: Patent expiration, increasing competition from biologics, reimbursement policies, and adherence issues threaten revenue stability.
• Financial Outlook: Moderate CAGR of approximately 4.5-5% anticipated from 2023–2027, contingent upon successful geographic expansion and innovation.
• Strategic Recommendations: Focus on formulary access strategies, explore line extensions, and diversify geographically to maintain market share.

---

FAQs

1. How does PENTASA compare to other mesalamine formulations?
   PENTASA's controlled-release formulation offers targeted delivery within the intestines, providing advantages in efficacy and tolerability. Competitors like Lialda and Apriso also offer controlled-release formulations with similar benefits, often differentiating through dosing convenience and regional presence.

2. What is the impact of patent expiry on PENTASA's sales?
   Patent expiry in key markets (e.g., U.S. 2011) has led to the proliferation of generics, resulting in significant price erosion and volume shifts toward low-cost suppliers, challenging PENTASA’s revenue stability.

3. Are biologics overtaking aminosalicylates in ulcerative colitis management?
   Not universally. For mild to moderate ulcerative colitis, aminosalicylates like PENTASA remain first-line. Biologics are primarily reserved for moderate to severe cases or refractory disease, although their rapid efficacy can impact mesalamine sales over time.

4. What regulatory trends could influence PENTASA’s market?
   Stricter HTA evaluations and price controls in Europe, coupled with Medicaid and private payer policies in the U.S., could constrain pricing and formulary inclusion. Emerging markets may offer regulatory hurdles but also growth potential.

5. What innovations could extend PENTASA’s product lifecycle?
   Advanced formulations (e.g., targeted delivery, enema or foam variants) and combination therapies could improve adherence and efficacy, sustaining market relevance amid increasing competition.

---

References

1. Global IBD Market Report (2022). IQVIA.
2. FDA Drug Approvals Calendar (2023). U.S. Food and Drug Administration.
3. European Medicines Agency (EMA). Regulatory Decisions on Mesalamine Formulations.
4. Almirall Annual Report (2022).
5. Marketline IBD Drugs Market Reports (2022-2027).

---

Note: Data points are estimates based on publicly available industry reports, patent databases, and market analyses as of early 2023.